Join our daily newsletter At The Bell to receive exclusive market insights
- Lumos Diagnostics (LDX) secures two new service agreements with Massachusetts-based women’s health company Hologic
- Under the deals, Lumos will conduct two programs of work for Hologic focused on the further development of a rapid point-of-care test product
- Lumos will receive up to US$1.5 million (A$$2.2 million) for its development services
- The programs are expected to be finished by mid-2023
- LDX shares are down 5.6 per cent and trading at 5 cents at market close
Diagnostic technology developer Lumos Diagnostics (LDX) has secured two new service agreements with Massachusetts-based Hologic.
Hologic, a medical technology company primarily focused on women’s health, engaged Lumos to conduct two programs of work focused on the further development of a rapid point-of-care test product,
These two programs are expected to be completed by mid-2023.
Under the agreement, Lumos will receive up to US$1.5 million (A$$2.2 million) for its development services.
“We have had a long-standing commercial relationship with Hologic and are delighted to be awarded these two services agreements to assist with the development of their women’s health products,” Lumos Diagnostics CEO Doug Ward said.
“I believe that strategic relationships which leverage Lumos’ intellectual property and know-how are likely to be a critical component of Lumos’ business plans going forward, so it is particularly pleasing that Hologic has been sufficiently impressed with our previous work to award us these two new services agreements.”
LDX shares were down 5.6 per cent and trading at 5 cents at market close.
